Literature DB >> 17324465

Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers.

Jorge L Alio1, Marta Abad, Alberto Artola, Jose L Rodriguez-Prats, Silvia Pastor, Jose Ruiz-Colecha.   

Abstract

PURPOSE: To investigate the potential role of autologous platelet-rich plasma in promoting healing in dormant corneal ulcers.
DESIGN: Prospective, consecutive, interventional, noncomparative, nonrandomized, observational study. PARTICIPANTS: Forty eyes of 38 patients with dormant corneal ulcers.
METHODS: Autologous platelet-rich plasma was used in a total of 40 eyes with dormant corneal ulcers divided into 2 groups: group I, 26 eyes treated with topical eyedrops of autologous platelet-rich plasma (12 neurotrophic, 9 herpetic, and 5 immunological ulcers), and group II, 14 eyes treated surgically with a solid clot of autologous platelet-rich plasma combined with amniotic membrane transplantation in perforated corneas or with impending perforation. The treatment was used in patients with chronic nonhealing ulcers (mean, 2 years of evolution) that had been unresponsive to conventional topical therapy. Autologous blood from each patient was obtained by venipuncture, and platelet-rich plasma was prepared from each blood sample without additives. MAIN OUTCOME MEASURES: Ulcer size, inflammation, healing, visual acuity, and patient's subjective symptoms.
RESULTS: Autologous platelet-rich plasma promoted healing of ulcers. In group I, 13 eyes healed, 11 eyes improved significantly, and 2 eyes showed no change. In group II, 10 eyes healed and 4 eyes improved significantly. Inflammation and subjective symptoms, particularly pain, improved in all patients. Vision remained stable or improved in all cases.
CONCLUSION: Autologous platelet-rich plasma promoted healing of dormant corneal ulcers even in eyes threatened by corneal perforation and was accompanied by a reduction in pain and inflammation.

Entities:  

Mesh:

Year:  2007        PMID: 17324465     DOI: 10.1016/j.ophtha.2006.10.044

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  31 in total

1.  Optimized preparation method of platelet-concentrated plasma and noncoagulating platelet-derived factor concentrates: maximization of platelet concentration and removal of fibrinogen.

Authors:  Jun Araki; Masahiro Jona; Hitomi Eto; Noriyuki Aoi; Harunosuke Kato; Hirotaka Suga; Kentaro Doi; Yutaka Yatomi; Kotaro Yoshimura
Journal:  Tissue Eng Part C Methods       Date:  2011-11-22       Impact factor: 3.056

2.  SIMTI recommendations on blood components for non-transfusional use.

Authors:  Giuseppe Aprili; Giorgio Gandini; Roberto Guaschino; Laura Mazzucco; Laura Salvaneschi; Stefania Vaglio
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

3.  Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis.

Authors:  Kyoung Min Kim; Yong-Tae Shin; Hong Kyun Kim
Journal:  Jpn J Ophthalmol       Date:  2012-09-13       Impact factor: 2.447

4.  Autologous Platelet-Rich Plasma Drops for Evaporative Dry Eye Disease from Meibomian Gland Dysfunction: A Pilot Study.

Authors:  Fahmeeda Murtaza; Dana Toameh; Hannah H Chiu; Eric S Tam; Sohel Somani
Journal:  Clin Ophthalmol       Date:  2022-07-06

Review 5.  [Autologous serum and alternative blood products for the treatment of ocular surface disorders].

Authors:  G Geerling; J D Unterlauft; K Kasper; S Schrader; A Opitz; D Hartwig
Journal:  Ophthalmologe       Date:  2008-07       Impact factor: 1.059

6.  Autologous Platelet-rich Plasma Eye Drops in the Treatment of Recurrent Corneal Erosions.

Authors:  Jun Hun Lee; Myung Jun Kim; Sang Won Ha; Hong Kyun Kim
Journal:  Korean J Ophthalmol       Date:  2016-03-25

Review 7.  Solid Platelet Rich Plasma in Corneal Surgery.

Authors:  Francisco Arnalich; Alejandra E Rodriguez; Alvaro Luque-Rio; Jorge L Alio
Journal:  Ophthalmol Ther       Date:  2016-05-14

8.  Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol.

Authors:  Passara Jongkhajornpong; Pawin Numthavaj; Thunyarat Anothaisintawee; Kaevalin Lekhanont; Gareth McKay; John Attia; Ammarin Thakkinstian
Journal:  BMJ Open       Date:  2021-06-30       Impact factor: 2.692

9.  Comparison of the effect of calcium gluconate and batroxobin on the release of transforming growth factor beta 1 in canine platelet concentrates.

Authors:  Raul F Silva; Jorge U Carmona; Cleuza M F Rezende
Journal:  BMC Vet Res       Date:  2012-07-25       Impact factor: 2.741

10.  Evaluation of the effect of calcium gluconate and bovine thrombin on the temporal release of transforming growth factor beta 1 and platelet-derived growth factor isoform BB from feline platelet concentrates.

Authors:  Raul F Silva; María E Alvarez; Diana L Ríos; Catalina López; Jorge U Carmona; Cleuza Mf Rezende
Journal:  BMC Vet Res       Date:  2012-11-06       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.